This story originally ran on Nov. 12.
Inverness Medical Innovations has terminated its contract with Thermo Fisher Scientific for the resale of Inverness' Biosite products.
The disclosure was made this week in a document filed by Thermo Fisher with the US Securities and Exchange Commission. The termination takes effect on July 1, 2010.
Inverness purchased Biosite in 2007. Among the products offered by Biosite are protein biomarker-based tests for congestive heart failure and cardiovascular diseases.